Dmitrij Kollins
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Renal Diseases and Glomerulopathies, Complement system in diseases, Platelet Disorders and Treatments, Monoclonal and Polyclonal Antibodies Research, Biosimilars and Bioanalytical Methods
Most-Cited Works
- → Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy(2024)129 cited
- → Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy(2023)112 cited
- → Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study(2023)55 cited
- → GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes(2016)33 cited
- → POS-546 EFFICACY AND SAFETY OF IPTACOPAN IN IgA NEPHROPATHY: RESULTS OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY AT 6 MONTHS(2022)31 cited
- → Safety and Immunogenicity of Rituximab Biosimilar GP2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis(2018)28 cited
- FOXP3+ regulatory T-cells in renal allografts: correlation with long-term graft function and acute rejection.(2011)
- → Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial(2020)21 cited
- → WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY(2024)7 cited
- → Lipoxygenase Products in the Urine Correlate with Renal Function and Body Temperature but not with Acute Transplant Rejection(2012)6 cited